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Abstract: The ventral tegmental area (VTA), an important source of dopamine, regulates goal- and
reward-directed and social behaviors, wakefulness, and sleep. Hyperactivation of dopamine neurons
generates behavioral pathologies. But any roles of non-dopamine VTA neurons in psychiatric illness
have been little explored. Lesioning or chemogenetically inhibiting VTA GABAergic (VTAVgat) neurons
generated persistent wakefulness with mania-like qualities: locomotor activity was increased; sensitivity
to D-amphetamine was heightened; immobility times decreased on the tail suspension and forced swim
tests; and sucrose preference increased. Furthermore, after sleep deprivation, mice with lesioned VTAVgat
neurons did not catch up on lost sleep, even though they were starting from a sleep-deprived baseline,
suggesting that sleep homeostasis was bypassed. The mania-like behaviors, including the sleep loss, were
reversed by valproate, and re-emerged when treatment was stopped. Lithium salts and lamotrigine,
however, had no effect. Low doses of diazepam partially reduced the hyperlocomotion and fully recovered
the immobility time during tail suspension. The mania like-behaviors mostly depended on dopamine,
because giving D1/D2/D3 receptor antagonists reduced these behaviors, but also partially on VTAVgat
projections to the lateral hypothalamus (LH). Optically or chemogenetically inhibiting VTAVgat terminals
in the LH elevated locomotion and decreased immobility time during the tail suspension and forced
swimming tests. VTAVgat neurons help set an animal’s (and perhaps human’s) mental and physical
activity levels. Inputs inhibiting VTAVgat neurons intensify wakefulness (increased activity, enhanced
alertness and motivation), qualities useful for acute survival. In the extreme, however, decreased or failed
inhibition from VTAVgat neurons produces mania-like qualities (hyperactivity, hedonia, decreased sleep).
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Abstract
The ventral tegmental area (VTA), an important source of dopamine, regulates goal- and reward-directed and social
behaviors, wakefulness, and sleep. Hyperactivation of dopamine neurons generates behavioral pathologies. But any roles of
non-dopamine VTA neurons in psychiatric illness have been little explored. Lesioning or chemogenetically inhibiting VTA
GABAergic (VTAVgat) neurons generated persistent wakefulness with mania-like qualities: locomotor activity was
increased; sensitivity to D-amphetamine was heightened; immobility times decreased on the tail suspension and forced swim
tests; and sucrose preference increased. Furthermore, after sleep deprivation, mice with lesioned VTAVgat neurons did not
catch up on lost sleep, even though they were starting from a sleep-deprived baseline, suggesting that sleep homeostasis was
bypassed. The mania-like behaviors, including the sleep loss, were reversed by valproate, and re-emerged when treatment
was stopped. Lithium salts and lamotrigine, however, had no effect. Low doses of diazepam partially reduced the
hyperlocomotion and fully recovered the immobility time during tail suspension. The mania like-behaviors mostly depended
on dopamine, because giving D1/D2/D3 receptor antagonists reduced these behaviors, but also partially on VTAVgat
projections to the lateral hypothalamus (LH). Optically or chemogenetically inhibiting VTAVgat terminals in the LH elevated
locomotion and decreased immobility time during the tail suspension and forced swimming tests. VTAVgat neurons help set
an animal’s (and perhaps human’s) mental and physical activity levels. Inputs inhibiting VTAVgat neurons intensify
wakefulness (increased activity, enhanced alertness and motivation), qualities useful for acute survival. In the extreme,
however, decreased or failed inhibition from VTAVgat neurons produces mania-like qualities (hyperactivity, hedonia,
decreased sleep).
Introduction
During the mania phase of bipolar disorder, patients sleep
little and have elevated mood (e.g., increased energy and
hyperactivity, impulsivity, decreased depression) [1–5]. In
mice, pathological hyperactivity and elevated mood can be
generated by various gene mutations and deletions: e.g.,
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ClockΔ19 [6], REV-erbα [7], ErbB4 tyrosine kinase dele-
tion in noradrenergic locus ceruleus cells [8], GSK-3β
overexpression [9], dopamine transporter knockdown
[10, 11], SHANK2 knockout [12], SHANK3 over-
expression [13], ANK3 disruptions [14], ionotropic gluta-
mate/AMPA receptor GluA1 knockout [15], ionotropic
glutamate/kainate GluK2 knockout [16], phospholipase c γ1
knockout [17], histidine triad nucleotide-binding protein 1
knockout [18], glutamate-cysteine ligase modifier unit
knockout [19], and the Na/K-ATPase α3 Myshkin (Myk/+)
mutation [20–22]. Some of these gene manipulations alter
excitation-inhibition (E-I) balance [8, 13, 15, 16, 23], and/or
elevate catecholamines [6–8, 10, 24], suggesting common
themes that could underlie the emergence of some types of
mania.
Both these themes come together in the ventral tegmental
area (VTA). The VTA an important source of dopamine,
regulates goal- and reward-directed and social behaviors
[25, 26], as well as wakefulness and sleep [27–29]. Exciting
VTA dopamine neurons with well-chosen rhythms can
produce mania-like behaviors in the day and euthymia at
night [30]. In addition to dopamine neurons, there is a rich
heterogeneity of glutamate and GABA neurons in the dif-
ferent anatomical subdomains of the VTA, and neuro-
transmitter co-release (e.g., dopamine -glutamate, GABA-
glutamate, GABA-dopamine) from VTA neurons is com-
mon [25, 31–33].
For this paper, we focus on the midline VTA, which
contains GABA (VTAVgat) and glutamate/nitric oxide syn-
thase (VTAVglut2) neurons [25, 28, 34–37]. These VTAVgat
and VTAVglut2/NOS1 neurons inhibit and excite, respectively,
the dopamine cells, but also, by projecting out of the VTA,
exert effects independent of dopamine [25, 28, 36]. The
VTAVgat neurons co-release GABA and glutamate [33], but
the majority of these VTA neurons’ actions locally are
GABAergic [28]. Locally they mostly inhibit VTAVglut2,
VTADA and VTAVglut2/DA cells, but also elicit a small
number of pure excitatory responses [28]. Chemogenetic
inhibition and chronic lesion of midline VTAVgat neurons
causes sustained wakefulness [28, 29], and excitation of
VTAVglut2 cells and VTA dopamine cells also causes
wakefulness [28, 27]. VTAVgat neurons limit arousal by
inhibiting dopamine neurons and via projections to the
lateral hypothalamus (LH) [28, 36, 38]; VTAVglut2 neurons
produce wakefulness, also independently of dopamine, by
projecting to the LH and nucleus accumbens [28].
Here, we characterize the type of wakefulness produced
by inhibiting or lesioning the VTAVgat neurons or exciting
VTAVglut2 neurons. We find that the wakefulness induced by
diminishing or removing VTAVgat neuron inhibition con-
tains behavioral endophenotypes that are mania-like, and
are treatable with valproate and diazepam, although not
with lithium or lamotrigine. On the other hand, the extended
but quiet wakefulness produced by activating midline
VTAVglut2 neurons has no endophenotypes characteristic of
mania. We suggest that the mania-like symptoms resulting
from diminished VTAVgat function are generated by chan-
ging the E-I balance in both the VTA and the LH.
Material and methods
Mice and housing
All experiments were performed in accordance with the UK
Home Office Animal Procedures Act (1986); all procedures
were approved by the Imperial College Ethical Review
Committee and the Ethics Committee for Animal Experi-
mentation of Xijing Hospital, Xi’an, and were conducted
according to the Guidelines for Animal Experimentation of
the Chinese Council institutes. The following strains of
mice were used: Vgat-ires-Cre: Slc32a1tm2(cre)Lowl/J kindly
provided by Lowell, JAX stock 016962 [39]; Vglut2-ires-
Cre: Slc17a6tm2(cre)Lowl/J, kindly provided by Lowell, JAX
stock 016963 [39]. Mice were maintained on a 12 h:12 h
light:dark cycle at constant temperature and humidity with
ad libitum food and water. The “lights-on” period started at
6:00 p.m. (18:00); the “lights-off” period started at 6:00 a.m.
(06:00). Lighting intensity was around 5 Lux during the red
light “lights off period”; and the white light level around
150 Lux during the “lights on” period.
AAV
pAAV-hSyn-DIO-hM4Di-mCherry, pAAV-hSyn-DIO-hM3Dq-
mCherry and pAAV-hSyn-DIO-mCherry were gifts from
Bryan L. Roth (Addgene plasmid 44362, 44361 and 50459)
[40]; pAAV-EF1α-DIO-taCASP3-TEV was a gift from Nirao
Shah (Addgene plasmid 45580) [41]; we packaged the
transgenes into AAV capsids (capsid serotype 1/2) in house
as described previously [42, 43]. rAAV2/9-EF1a-DIO-
eNpHR3.0-mCherry and rAAV2/9-EF1a-DIO-ChR2-mCherry
were packaged by BrainVTA (Wuhan, China).
Surgery
10–12-week-old male mice were anesthetized with 2%
isoflurane in oxygen by inhalation and received buprenor-
phine (0.1 mg/kg) and carprofen (5 mg/kg) injections, and
then placed on a stereotaxic frame (Angle Two, Leica
Microsystems, Milton Keynes, Buckinghamshire, UK). The
AAV was injected through a stainless steel 33-gauge/
15 mm/PST3 internal cannula (Hamilton) attached to a 10 µl
Hamilton syringe, at a rate of 0.1 µl min−1. For the
AAV injections, virus was bilaterally injected into the VTA,
50 nl for each side of the VTA. The injection co-
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ordinates were VTA: (ML= ±0.35 mm, AP=−3.52 mm,
DV=−4.25 mm). After injection, the cannula was left at
the injection site for 5 min and then slowly pulled out. After
injections, mice that were to undergo the sleep experiments
were implanted with three gold-plated miniature screw
electrodes (–1.5 mm Bregma, +1.5 mm midline; +1.5 mm
Bregma, –1.5 mm midline; –1 mm Lambda, 0 mm midline
—reference electrode) with two EMG wire (AS634, Cooner
Wire, CA). The EMG electrodes were inserted between the
neck musculature. The Neurologger 2A EEG-EMG device
[44] was affixed to the skull with Orthodontic Resin power
and Orthodontic Resin liquid (Tocdental, UK). For the fiber
optogenetic and chemogenetic experiments, after virus
injection above the VTA (ML= ±0.35 mm; AP=
−3.52 mm; DV=−4.25 mm), mice received surgical
bilateral implantations above the LH of a monofiberoptic
cannula (ML= ±0.36 mm; AP=−3.54 mm; DV=
−4.0 mm) (200 µm; Doric Lenses, Inc., Quebec, Canada) or
guide cannula (ML= ±0.36 mm; AP=−3.54 mm; DV=
−3.5 mm) (World precision instruments, USA) for
clozapine-N-oxide (CNO) delivery.
Drug treatments
For all drug treatments, mice first received vehicle injections,
and behavioral tests were performed; 2 weeks later, the same
group of mice were given drug injections, and behavioral
tests were performed. For the long-term valproate treatments,
we further tested mice behaviors 2 weeks after valproate
treatment was withdrawn. Baseline behaviors of the mice
were tested during this period without any treatment.
Chemogenetics
CNO (C0832, Sigma-Aldrich, dissolved in saline, 1 mg/kg)
or saline was injected i.p. 30 min before the start of the
behavioral tests. For VTAVgat-hM4Di mice or VTAVglut2-
hM3Dq mice, CNO or saline was injected during the “lights
off” active phase. 1 μl of 1 mM CNO was infused into the
LH through the guide cannula at a rate of 0.1 µl min−1 with
an injector needle (33-gauge, Hamilton)
D-amphetamine
D-Amphetamine (2813/100, Tocris Bioscience, dissolved in
saline, 2 mg/kg) or saline was injected i.p. into the mice
[13, 21], and the mice were assessed directly after D-
amphetamine injection.
Valproate, lithium, diazepam, and lamotrigine
Sodium valproate (2815, TOCRIS, dissolved in saline,
200 mg/kg), LiCl (Sigma-Aldrich, dissolved in saline,
100 mg/kg) or saline (vehicle) was injected i.p. into the
mice. For acute treatments (repeated injections) with lithium
or valproate, mice received vehicle injections, and then
behaviors (locomotion and tail-suspension) were tested;
after 2 weeks, the same group of mice were given lithium or
valproate injections. For the Li–H2O treatment, mice were
treated with LiCl in drinking water (300 mg/L) for 2 weeks.
Mice were first given normal water, and behaviors were
tested, and the same group of mice were placed on Li–H2O
for 2 weeks. Valproate or LiCl treatments were as pre-
viously reported [13, 17]: valproate or LiCl were injected
three times (10:00, 14:00 and 17:00) one day before the
behavioral assays; and during the day of the behavioral
assay, valproate or LiCl was injected two times (10:00,
14:00). Locomotion or tail-suspension tests were performed
30 min after injection (14:30). After the locomotion or tail-
suspension tests (see below), mice received a final valproate
injection (17:00), and then the 24-h sleep–wake recordings
were then performed (see section “EEG analysis,
sleep–wake behavior and sleep deprivation”).
Diazepam (2805, TOCRIS, dissolved in 0.9% saline
containing 0.1% Tween 80, 1 mg/kg) and lamotrigine
(1611, TOCRIS, diluted in 0.9% saline, 10 mg/kg) or their
control vehicles were injected i.p. into the mice. For single
treatments with diazepam (1 mg/kg) or lamotrigine (10 mg/
kg), mice received vehicle injections, and then behaviors
(locomotion and tail-suspension) were tested; after 2 weeks,
the same group of mice were given diazepam or lamotrigine
injections (14:00). For repeated treatments, diazepam (1 mg/
kg) or lamotrigine (10 mg/kg) were injected three times
(10:00, 14:00, and 17:00) 1 day before the behavioral
assays; and during the day of the behavioral assay, diaze-
pam or lamotrigine were injected two times (10:00, 14:00).
The locomotion or tail-suspension tests were performed
30 min after injection (14:30).
Serum lithium
Blood samples were collected before and after lithium
injections via transcutaneous cardiac puncture and the
serum was separated for determination of lithium levels.
Mice were maintained on anesthesia and blood samples
were collected directly from the left ventricle before killing
them. Serum lithium was analyzed using a Roche Cobas
c311 analyzer.
Dopamine receptor antagonists experiment
Dopamine antagonists SCH-23390 (0.03 mg/kg, dissolved
in saline) and raclopride (1 mg/kg, dissolved in saline), for
D1 and D2/D3 receptors, respectively, were injected serially
i.p. into the VTAVgat-mCherry mice or VTAVgat-CASP3
mice 20 min before the locomotion, tail-suspension test
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(TST), or sleep experiment. For the experiments with che-
mogenetic inhibition combined with dopamine receptor
antagonists, SCH-23390 and raclopride were injected serially
i.p. into the VTAVgat-hM4Di mice, and 20min later, saline or
CNO was injected into the antagonists-injected mice, and
30min later, the locomotion test and TST was performed.
Locomotor activity
The locomotor activity and time spent in stereotypy was
detected in an activity test chamber (Med Associates, Inc)
with an ANY-maze video tracking system (FUJIFILM co.)
and measured by ANY-maze software (Stoelting Co. US.).
VTAVgat-mCherry or VTAVgat-CASP3 mice were directly
put into the activity test chamber; for VTAVgat-hM4Di mice,
the mice were put into the test chamber 30 min after saline
or CNO injection; for D-Amphetamine experiments,
mice were first put into chamber for 30 min, and the mice
received vehicle or amphetamine injections. The locomotor
activity was detected straight after injection for 1-h.
Home cage activity
Mice were habituated in the cage for 24 h with mock
Neurologgers before recordings. The home cage activities
were then recorded using the accelerometer built into the
Neurologger 2A devices [44] for a 24-h period and analyzed
using Spike2 software.
Tail-suspension test (TST)
The TST was performed as described [13]. After a habi-
tuation period in the test room, mice were suspended 60 cm
above the floor by their tails by taping the tail tip. Behaviors
were video recorded and blindly scored manually and
measured by ANY-maze software (Stoelting Co. US).
Forced swimming test (FST)
Mice were placed in a borosilicate glass cylinder (5 L,
18 cm diameter, 27 cm high) filled with water (25 °C, water
depth 14 cm) for 6 min. The immobility time during the last
4 min was manually measured. Immobility time was defined
as the time spent without any movements except for a single
limb paddling to maintain flotation.
Sucrose preference test (SPT)
This was a 2-choice test between 1% sucrose and water.
Mice were habituated to a dual delivery system (one bottle
with water and one bottle with 1% sucrose) for 3 days.
Sucrose preference was then assessed over 3 consecutive
days. For the chemogenetic experiments, animals were
water-restricted overnight before saline or CNO injection.
30 min after saline or CNO injection, the mice were given
free access to the 2-water delivery system for 4 h. Sucrose
preference (%) was calculated as (weight of sucrose con-
sumed)/(weight of water consumed+weight of sucrose
consumed) × 100%.
Elevated plus maze test
The elevated plus maze apparatus (Global Biotech Inc.
Shanghai) was opaque and consisted of a central platform
(10 cm × 10 cm), two open arms (50 cm × 10 cm), and two
closed arms (50 cm × 10 cm) with protective walls 40 cm
high, which was 70 cm above the ground. Animals were
placed in the central platform facing one open arm of the
apparatus and were free to explore the arms for 5 min. The
apparatus was cleaned with 75% ethanol before and after
each session. The traces were recorded by an overhead
camera and shown by average heatmap of each group. The
ratio of exploring time in the open arm was calculated by
Video Tracking Software (ANY-maze, Stoelting Co., Ltd.).
Timing of behavioral tests
10–12 weeks male mice were given virus injection (see
“Surgery” section), and 4–6 weeks after this, behavioral
tests were performed (the mice were ~14–18 weeks old by
this stage), or drug treatments were started. During the drug
treatment experiments, after vehicle injections, behavioral
tests were performed (the mice were ~14–18 weeks old);
and 2 weeks later, mice received drug injection, and beha-
vioral tests were performed (by this stage, the mice were
~16–20 weeks old). All behavioral tests (locomotion, TST,
forced swimming test (FST), or sucrose preference test
(SPT)) took place during the “lights-off” phase of the light-
dark cycle, when the mice were most active, particularly
between 14:00 p.m.–17:00 (2 p.m.–5 p.m.), except for the
sleep deprivation experiments (see section “EEG analysis,
sleep–wake behavior, and sleep deprivation”).
Mouse groupings for behavioral tests
For chemogenetic experiments, VTAVgat-hM4Di mice were
randomly split into two groups that received saline or CNO
injection, and the locomotion test, TST, FST, or SPT were
then performed. After 1–2 weeks, the same mice were given
CNO or saline injection, and the locomotion test, TST, FST,
or SPT were again performed. For the saline control
experiments, VTAVgat-hM4Di mice received saline injec-
tions, and then the locomotion test, TST, FST, or SPT were
performed, and after 1–2 weeks, the same mice were given
saline injection, and the locomotion test, TST, FST, or SPT
were performed.
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EEG analysis, sleep–wake behavior, and sleep
deprivation
EEG and EMG signals were recorded using Neurologger 2A
devices [28, 44]. NREM sleep and wake states were auto-
matically classified using a sleep analysis software Spike2
and then manually scored. The sleep deprivation protocol
was as described previously [45]. At the start of “lights on”
period, when sleep pressure is the highest, mice fitted with
Neurologgers were put into novel cages, and at 1-h intervals,
novel objects were introduced. After 5 h sleep deprivation,
mice were then put back into their home cages for 19 h. In
total, a 24-h sleep–wake state was recorded. For the sleep
experiments with dopamine receptor antagonists, mice were
given SCH-23390 (0.03 mg/kg) and raclopride (2mg/kg)
injections in the middle of the “lights off” active period.
Optogenetic stimulation
For the optogenetic behavioral experiments, a fiber patch
cord was connected to the laser generator, and dual optic
fibers were connected to the fiber patch through a rotary joint
(ThinkerTech Nanjing BioScience Inc. China.). Before the
experiments, a monofiberoptic cannula was connected to the
fiber patch cord. VTAVgat-eNpHR-mCherry→LH mice or
VTAVgat-ChR2-mCherry→LH mice were bilaterally opto-
stimulated (20 Hz, 0.5 s duration with 0.5 s interval, 593 nm,
20 μW) in the LH during the “lights off” phase. The stimu-
lation was given for the duration of the behavioral tests.
Immunohistochemistry
These procedures were carried as described previously [28].
Primary antibodies used were rat monoclonal mCherry
(1:2000, Thermo Fisher, M11217); mouse monoclonal TH
(1:2000, Sigma, T2928); secondary antibodies were Alexa
Fluor 488 goat anti-mouse (1:1000, Invitrogen Molecular
Probes, A11001), Alexa Fluor 594 goat anti-rat (1:1000,
Invitrogen Molecular Probes, A11007). Slices were moun-
ted on slides, embedded in Mowiol (with 4,6-diamidino-2-
phenylindole), cover-slipped, and analyzed using an upright
fluorescent microscope (Nikon Eclipse 80i, Nikon).
Slice electrophysiology
Three weeks after injection of AAV2/9-hSyn-DIO-hM3Dq-
mCherry into the VTA of VGlut2-Cre mice, brain slices
containing the VTA were prepared for electrophysiological
recordings. Mice were anesthetized with isoflurane and then
killed. Brains were rapidly removed and placed in ice-cold
oxygenated cutting ACSF (containing in mM: 252 sucrose,
2.5 KCl, 6 MgSO4, 0.5 CaCl2, 1.2 NaH2PO4, 2.5 NaHCO3, 10
glucose). Horizontal VTA slices (300 μm) were cut using a
vibratome (VT1200S, Leica). Brain slices containing the VTA
were transferred to recording ACSF with 124mM NaCl,
2.5mM KCl, 1.2mM NaH2PO4, 2 mMMgSO4, 2 mM CaCl2,
24mM NaHCO3, 5 mM HEPES and 12.5mM glucose. Brain
slices were incubated at 34 °C for 30min and were then kept
at room temperature under the same conditions for 45min
before transfer to the recording chamber at room temperature
(22–25 °C). The ACSF was perfused at 2mL/min. The brain
slices were visualized with a fixed upright microscope
(BX51WI, Olympus) equipped with a water immersion lens
(40×/0.8W) and a digital camera (C13440, Hamamatsu).
Patch pipettes were pulled from borosilicate glass capillary
tubes using a pipette puller (P97, Sutter). The resistance of
pipettes varied between 3 and 5MΩ. For current clamp
recording of action potentials, pipettes were filled with solution
(130mM potassium gluconate, 4 mM KCl, 1mM MgCl2,
4 mM ATP-Mg, 10mM phosphocreatine, 0.3 mM EGTA,
0.3mM GTP-Na, 10mM HEPES, pH 7.3). The hM3Dq-
mCherry-positive neurons in the VTA were patched in
current-clamp mode. We injected a constant positive current to
bring the membrane potential to around −45mV to induce
stable and persistent AP firing. CNO (100 μM) was bath
applied. The signals were recorded with a MultiClamp 700B
amplifier (Molecular Devices), Digidata 1550 interface, and
Clampex 10.6 software (Molecular Devices).
Quantification and statistics
Statistical tests were run in “Origin 2019b” (Origin Lab).
The individual tests, and the number (n) of mice for each
experimental group/condition, are given in the figure
legends. All data are given as mean ± SEM and ‘center
values’ are the means. We tested for normality and equal
variances. When the data were non-normal, we used non-
parametric tests (stated in relevant figure legends). Mice
were assigned randomly to the experimental and control
groups. For chemogenetic experiments, saline or CNO
injection was blinded. For analyzing chronic lesioning
experiments, VTAVgat-mCherry and VTAVgat-CASP3 mice,
experimenters were blinded. For drug treatments, vehicle or
drug injections were not done blinded. Experimental data
analysis, including animal behavior that was scored from
videos and the analysis of EEG data, was done blinded.
Results
Chemogenetic inhibition or lesioning of VTAVgat
neurons produces increased locomotor activity and
sensitivity to amphetamine
We delivered AAV-DIO-hM4Di-mCherry into the VTA of
Vgat-ires-cre mice to express hM4Di-mCherry (an inhibitory
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receptor activated by the CNO ligand [40]) specifically in
VTAVgat neurons to generate VTAVgat-hM4Di mice (Fig. 1a)
[28]. As previously [28], we also ablated VTAVgat neurons by
injecting AAV-DIO-CASP3 and/or AAV-DIO-mCherry (as
a control) into the VTA of Vgat-ires-cre mice to generate
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Chemogenetic inhibition of VTAVgat neurons Chronic lesioning of VTAVgat neuronsa b
hM4Di-mCherry mouse
mCherry mouse CASP3 mouse
VTAVgat-hM4Di mice injected with saline or CNO VTAVgat-mCherry or -CASP3 mice
Fig. 1 Selective inhibition or lesioning of VTAVgat neurons
increased locomotor activity and sensitivity to D-amphetamine-
induced hyperlocomotion. a Generation of VTAVgat-hM4Di mice.
Staining by immunohistochemistry (mCherry, red) for hM4Di-
mCherry expression in the VTA. Scale bar: 150 μm. b Generation of
VTAVgat-CASP3 and VTAVgat-mCherry control mice. Immunohisto-
chemical staining for mCherry (red) and dopamine neurons (TH, tyr-
osine hydroxylase, green) in the VTA of control mice that expressed
mCherry in VTAVgat neurons (left-hand images), or in mice where
VTAVgat neurons were lesioned with caspase (right-hand images).
Scale bar: 150 μm. c Video-tracked paths, locomotion speed and dis-
tance traveled of VTAVgat-hM4Di mice (n= 8 mice) following CNO
(1 mg/kg) injection compared with saline injection in the open field
over a 30-min period. Paired t-test, t (7)=−3.68, **p= 0.007.
d Video-tracked paths, locomotion speed and distance traveled
of VTAVgat-mCherry (n= 8 mice) and VTAVgat-CASP3 mice (n= 9
mice) in the open field over a 30-min period. Unpaired t-test, t(15)=
−5.43, ****p= 0.00006. e Locomotion speed and distance traveled of
VTAVgat-hM4Di mice (n= 6 mice) in the open field after saline or D-
amphetamine injection (subsequent to saline or CNO injection).
Repeated measures two-way ANOVA and Bonferroni-Holm post
hoc test. F(1,5)= 66. Saline vs. saline+ amphetamine t(5)= 3.69,
*p= 0.01; CNO vs. CNO+ amphetamine t(5)= 13.6, ****p=
0.000038. f Locomotion speed and distance traveled in the open
field test of VTAVgat-mCherry (n= 7 mice) or VTAVgat-CASP3 mice
(n= 6 mice) after vehicle or D-amphetamine injection. Two-way
ANOVA and Bonferroni-Holm post hoc test. F(mCherry or CASP3)= 93;
F(saline or amphetamine)= 26; F(interaction)= 5.64; mCherry+ vehicle vs.
mCherry+ amphetamine t(6)=−3.39, *p= 0.01; CASP3+ vehicle
vs. CASP3+ amphetamine t(5)=−4.97, **p= 0.004. All error bars
represent the SEM.
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respectively. After 5–6 weeks post-injection, mCherry-
positive VTAVgat neurons were detected in control mice
that had only received AAV-DIO-mCherry injections,
whereas mCherry-positive VTAVgat neurons were mostly
absent in caspase-injected mice (Fig. 1b), but tyrosine
hydroxylase-positive (dopamine) neurons were still present
(Fig. 1b).
We next assessed locomotion behaviors of these animals.
After CNO injection, VTAVgat-hM4Di mice had higher
locomotor activity in an open-field arena with more distance
traveled (Fig. 1c) and had elevated average and maximum
speeds over 30 min compared with saline-injected VTAVgat-
hM4Di mice (Supplementary Fig. 1a). As a control, the
locomotor baseline activity of VTAVgat-hM4Di mice did not
differ over the extended experimental period: mice that
received an initial saline injection, and then another saline
injection two weeks later, had the same locomotor activity
(Supplementary Fig. 1b). Consistent with these chemoge-
netic inhibition results, VTAVgat-CASP3 mice also pro-
duced hyperlocomotion in the open field—more distance
traveled (Fig. 1d), and higher average and maximum speeds
over 30 min compared with the distance traveled by
VTAVgat-mCherry control mice (Fig. 1d; Supplementary
Fig. 1c). VTAVgat-CASP3 mice were also hyperactive in
their home cages (Supplementary Fig. 1d). Notably, the
hyperlocomotion of the VTAVgat-CASP3 mice was still seen
when the mice were retested in the open field four months
post-lesion (Supplementary Fig. 1e). By the end of this
period, the body weight of VTAVgat-CASP3 mice was
reduced compared with that of VTAVgat-mCherry control
mice (Supplementary Fig. 1f).
Mice suggested to have mania-like characteristics, or
patients with bipolar-related mania, are hypersensitive to D-
amphetamine [13, 21], whereas mice and patients posited to
have an attention deficit hyperactivity (ADHD)-like dis-
order become less active with D-amphetamine [46, 47].
Treating CNO-injected VTAVgat-hM4Di mice and VTAVgat-
CASP3 mice with D-amphetamine significantly increased
their locomotion speed above their high baseline speed,
and increased the distance traveled (Fig. 1e, f) and the
time spent in stereotypy (Supplementary Fig. 1g, h), sug-
gesting that both groups of mice (VTAVgat-CASP3
and CNO-injected VTAVgat-hM4Di mice) were not
ADHD-like.
Acute inhibition or chronic lesioning of VTAVgat
neurons elevates mood
We assessed mood-related behaviors using TST, FST, SPT,
and the elevated plus maze. During the TST, the immobility
times of CNO-injected VTAVgat-hM4Di mice and VTAVgat-
CASP3 mice were greatly decreased compared
with saline-injected VTAVgat-hM4Di control mice and
VTAVgat-mCherry (Fig. 2a, b). Both CNO-injected
VTAVgat-hM4Di mice and VTAVgat-CASP3 mice also had
decreased immobility times during the FST compared with
saline-injected or VTAVgat-mCherry controls (Fig. 2c, d).
This could suggest that reducing VTAVgat neuronal output,
by either chemogenetic inhibition or lesioning, produces
less depressive-like behaviors. In addition, during the SPT,
CNO-injected VTAVgat-hM4Di mice and VTAVgat-CASP3
mice consumed more sucrose than their control littermates
(Fig. 2e, f), possibly indicating a raised hedonic state. As a
control, the baseline behavior of VTAVgat-hM4Di mice did
not differ over the extended experimental period: mice that
received an initial saline injection, and then another saline
injection 2 weeks later, had the same performance during
the TST, FST, or SPT (Supplementary Fig. 1i). We char-
acterized the anxiety-like behavior of our mouse models
using the elevated plus maze. The time spent in the open
arms of the maze by both CNO-injected VTAVgat-hM4Di
mice and VTAVgat-CASP3 mice increased (Fig. 2g, h),
suggesting their anxiety was reduced.
Mice with lesioned VTAVgat neurons have less sleep
need after sleep deprivation
VTAVgat-CASP3 mice have a long-term sleep deficit [28].
To further characterize the need of VTAVgat-CASP3 mice
for sleep, we performed a sleep deprivation experiment.
After sleep deprivation, there is usually a rebound in lost
NREM sleep, a process termed sleep homeostasis [48].
Mice were kept awake for 5 h with novel objects presented
each hour and were then tested to see if they caught up on
lost sleep in their home cage. Control VTAVgat-mCherry
mice had rebound NREM sleep after 5 h sleep deprivation,
and thereby after 19 h they had regained 90% of their sleep
loss (Fig. 2i). Surprisingly, the VTAVgat-CASP3 mice,
despite already starting from a chronic sleep-deprived
baseline, did not catch up on lost NREM sleep after 5 h
continuous sleep deprivation (Fig. 2i).
The mania-like behavior produced by lesioning
VTAVgat neurons can be pharmacologically rescued
by valproate and diazepam but not lithium or
lamotrigine
We assessed if lithium could treat the manic-like state of
VTAVgat-CASP3 mice. We confirmed that serum lithium
was elevated to therapeutic levels during the acute treatment
(Supplementary Fig. 2a), and that the behavioral baselines
of VTAVgat-mCherry or VTAVgat-CASP3 mice did not
change during the treatment period (Supplementary
Fig. 2b–f). However, neither acute (100 mg/kg) (Supple-
mentary Fig. 3a–e) nor chronic (300 mg/L) treatments
(Supplementary Fig. 3f–j) had any effects (Of note, chronic
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Li-H2O treatment decreased the immobility time of control
mice during the TST (Supplementary Fig. 3i)).
We next examined valproate (200 mg/kg) treatments
(Fig. 3a). Acute injection of valproate did not affect the
locomotor activity of VTAVgat-mCherry control mice
(Fig. 3b). By contrast, the hyperlocomotor activity of
VTAVgat-CASP3 mice in the open field was restored down
to control levels by valproate treatment (Fig. 3c). However,
2 weeks after the acute valproate treatment was withdrawal
from VTAVgat-CASP3 mice, their hyperactivity in the open
field had returned (Fig. 3c). Similarly, during the tail
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VTAVgat-mCherry control mice (Fig. 3d), but significantly
increased the immobility time of VTAVgat-CASP3 mice
back up to control levels (Fig. 3e). Two weeks after
valproate had been removed, however, the abnormally high
agitation of VTAVgat-CASP3 mice had re-emerged (Fig. 3e).
We assessed if valproate could reduce the sustained
wakefulness of VTAVgat-CASP3 mice. The wake time of
VTAVgat-CASP3 mice significantly decreased after treat-
ment with valproate, whereas NREM sleep time sub-
stantially increased (Fig. 3f). VTAVgat-CASP3 mice also
have a pathological sleep architecture with fewer episodes
of wake and NREM sleep, prolonged duration of each wake
episode, and substantially decreased numbers of wake-
NREM transitions [28]. Valproate treatment normalized the
sleep–wake architecture of the VTAVgat-CASP3 mice: the
episode number (Supplementary Fig. 4a), episode duration
of wake was restored to control levels (Supplementary
Fig. 4b), as were the number of transitions between wake
and NREM sleep (Supplementary Fig. 4c).
We next tested if a low dose of the GABAA receptor
positive allosteric modulator diazepam, an anxiolytic,
influenced the behavior of VTAVgat-CASP3 mice (Supple-
mentary Fig. 5a–j). Treatment of VTAVgat-CASP3 mice
with either single or repeated doses of 1 mg/kg diazepam
partially reduced the hyperlocomotion (Supplementary
Fig. 5c, h) and fully recovered the immobility time during
the TST (Supplementary Fig. 5e, j). These results suggest
that diazepam has a potential treatment effect on VTAVgat-
CASP3 mice.
We also treated VTAVgat-CASP3 mice with another anti-
epilepsy and bipolar disorder drug—lamotrigine
(Supplementary Fig. 6a–j). Lamotrigine (10 mg/kg)
decreased the locomotion (Supplementary Fig. 6b, g) and
immobility time during the TST (Supplementary Fig. 6d, i)
of VTAVgat-mCherry mice. However, lamotrigine had no
effect on treatment of VTAVgat-CASP3 mice. Neither
locomotion (Supplementary Fig. 6c, h) nor immobility time
during TST (Supplementary Fig. 6e, j) were affected.
Note: with the exception of chronic lithium treatment,
none of these drug treatments affected the overall body
weight of the mice during and after treatments (Supple-
mentary Fig. 7a–d); body weight was reduced during
chronic lithium treatment (Supplementary Fig. 7c).
The extended wakefulness produced by activating
VTAVglut2 neurons is not mania-like
Activating VTAVglut2 neurons also promotes wakefulness
[28]. To investigate if this type of artificially-induced wake
is also mania-like, we expressed the excitatory chemoge-
netic hM3Dq receptor in VTAVglut2 neurons (VTAVglut2-
hM3Dq mice; Fig. 4a) [8]. We prepared acute brain slices
containing the VTA from VTAVglut2-hM3Dq mice, and first
confirmed that CNO application triggered action potentials
in hM3Dq-mCherry-expressing cells in VTA glutamatergic
neurons (Fig. 4b). Chemogenetic activation of VTAVglut2
neurons by CNO injection did not alter the locomotor
activity or distance traveled of VTAVglut2-hM3Dq mice
compared with saline injected mice (Fig. 4c) (see also data
in 28). Moreover, the immobility time during the TST and
FST did not differ between CNO injected- and saline
injected VTAVglut2-hM3Dq mice (Fig. 4d, e). This data
serves as an internal negative control, showing that not all
artificially induced wakefulness in mice will be mania-like:
the activation of VTAVglut2 neurons did not produce
hyperactivity and mood-related deficits, suggesting a dif-
ferent kind of wakefulness from that generated by inhibition
of VTAVgat neurons.
VTA GABAergic neurons contribute to mania-like
behaviors via dopamine signaling and projections
to the LH
To examine whether the hyperactive behaviors in the CNO-
injected VTAVgat-hM4Di mice or VTAVgat-CASP3 mice
were produced by increased dopamine signaling, we gave a
dopamine receptor antagonist mixture i.p. (containing SCH-
23390 and raclopride for D1 and D2/D3 receptors, respec-
tively) (these antagonists were given prior to saline or CNO
injection to VTAVgat-hM4Di mice). In the open-field test,
the dopamine antagonists reduced the hyperlocomotion and
distance traveled of saline-injected VTAVgat-hM4Di and
VTAVgat-mCherry control mice (Fig. 5a, b), and also lar-
gely reduced the hyperlocomotion of CNO-injected
Fig. 2 Dysfunction of VTAVgat neurons elevates mood and impairs
sleep homeostasis. a Immobility time during the tail suspension test
(TST) of VTAVgat-hM4Di mice (n= 8 mice) after saline or CNO
injection. Paired t-test, t(7)= 53.8, ****p= 1.98e−10. b Immobility
time during the during TST of VTAVgat-CASP3 (n= 9 mice) or
VTAVgat-mCherry mice (n= 8 mice). Unpaired t-test, t(15)= 14.3,
****p= 3.7e−10. c Immobility time during the forced swimming test
(FST) of VTAVgat-hM4Di mice (n= 6 mice) after saline or CNO
injection. Paired t-test, t(5)= 5, **p= 0.003. d Immobility time dur-
ing the FST of VTAVgat-CASP3 (n= 6 mice) or VTAVgat-mCherry
mice (n= 6 mice). Unpaired t-test, t(10)= 6, ***p= 0.0001.
e Sucrose preference of VTAVgat-hM4Di mice (n= 6 mice) after saline
or CNO injection. Paired t-test, t(5)=−3.5, *p= 0.01. f Sucrose
preference of VTAVgat-CASP3 (n= 6 mice) or VTAVgat-mCherry mice
(n= 8 mice). Unpaired t-test, t(12)=−4.8, ***p= 0.0004. g Elevated
plus maze: VTAVgat-hM4Di mice received saline injection and two
weeks later a second saline injection (n= 8 mice), paired t-test, t(7)=
−1.06, p= 0.32; or saline and 2 weeks later a CNO injection (n= 8
mice), paired t-test, t(7)=−5.28, **p= 0.001. h Elevated plus maze
of VTAVgat-CASP3 (n= 6 mice) or VTAVgat-mCherry mice, paired
t-test, t(5)=−3.45, *p= 0.01. i The accumulative recovery sleep
(time in NREM sleep) after 5 h of sleep deprivation (SD) of VTAVgat-
CASP3 (n= 4 mice) or VTAVgat-mCherry mice (n= 4 mice).
Mann–Whitney test, *p= 0.03. The light and dark shading represents
the “lights on” and “lights off” phases.
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VTAVgat-hM4Di mice (Fig. 5a), but only had a partial effect
on VTAVgat-CASP3 mice (Fig. 5b). In the TST, dopamine
receptor antagonists increased the immobility time of
both saline- or CNO-injected VTAVgat-hM4Di mice and
VTAVgat-mCherry control or VTAVgat-CASP3 mice
(Fig. 5c, d). However, the immobility time of CNO-injected
VTAVgat-hM4Di mice or VTAVgat-CASP3 mice that
received dopamine receptor antagonist injection was still
significantly lower than saline-injected VTAVgat-hM4Di























































































































































































































VTAVgat-mCherry mice VTAVgat-CASP3 mice






Treatment of VTAVgat-CASP3 mice with valproate
Fig. 3 Valproic acid can successfully treat the mania-like behavior
of VTAVgat-CASP3 mice. a Pharmacological treatment protocol for
valproic acid. The top arrows indicate vehicle or valproic acid injec-
tion (depending on mouse group) and the stars indicate when the
behavioral experiments were undertaken. b Locomotion speed and
distance traveled for VTAVgat-mCherry mice (n= 6 mice) that received
either vehicle or valproic acid treatment. Paired t-test, t(5)=−0.36,
p= 0.73. c Locomotion speed and distance traveled for VTAVgat-
CASP3 mice (n= 6 mice) received either vehicle or valproic acid
treatment, or where the valproic acid treatment had been removed for
2 weeks. Repeated measures one-way ANOVA and Bonferroni-Holm
post hoc test. F(2,10)= 47; vehicle vs. valproate t(10)= 8.68,
****p= 0.000005; valproate vs. 2 weeks after valproate withdrawal
t(10)= 8.19, ****p= 0.000009; vehicle vs. after valproate withdrawal
t(10)= 0.48, p= 0.63. d Time spent immobile on the TST of VTAVgat-
mCherry mice (n= 6 mice) received vehicle or valproate injection.
Paired t-test, t(5)= 0.71, p= 0.5. e Time spent immobile on the TST
of VTAVgat-CASP3 mice (n= 6 mice) received vehicle, valproate
injection, or 2 weeks after valproate withdrawal. Repeated measures
one-way ANOVA and Bonferroni-Holm post hoc test. F(2,10)= 32;
vehicle vs. valproate t(10)= 7.41, ****p= 0.00002; 2 weeks after
valproate withdrawal; t(10)= 6.32, ****p= 0.00008; vehicle vs.
remove t(10)= 1.08, p= 0.3. f Percentage and time of wake and
NREM for VTAVgat-mCherry mice and VTAVgat-CASP3 mice over the
12 h “lights off” period that received saline or valproate injection.
mCherry+ vehicle n= 6 mice; mCherry + valproate n= 5 mice;
CASP3+ vehicle n= 6 mice; CASP3+ valproate n= 7 mice. Two-
way ANOVA and Bonferroni-Holm post hoc test. Wake: F(mCherry or
CASP3)= 66; F(Vehicle or valproate)= 17; F(interaction)= 21; mCherry +
vehicle vs. mCherry + valproate t(9)= 0.38, p= 0.38; CASP3+
vehicle vs. CASP3+ valproate t(11)= 6.89, ****p= 0.00002.
NREM: F(mCherry or CASP3)= 65; F(Vehicle or valproate)= 32; F(interaction)=
20; mCherry+ vehicle vs. mCherry + valproate t(9)=−0.92, p=
0.37; CASP3+ vehicle vs. CASP3+ valproate t(11)=−6.85,
****p= 0.00002. All error bars represent the SEM.
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receptor antagonists (Fig. 5c, d). We also found that the
extended wakefulness of VTAVgat-CASP3 mice was sub-
stantially attenuated by the dopamine receptor antagonists
(Supplementary Fig. 8a, b). The above results suggest that
blocking dopamine signaling substantially reduces the
mania-like behaviors of VTAVgat-CASP3 mice.
VTAVgat neurons project prominently to the LH [28]. We
conducted optogenetic and chemogenetic experiments to
examine if the VTAVgat to LH projection contributes to
hyperactivity and mood-related behaviors. An AAV carry-
ing a Cre-dependent eNpHR3.0-mCherry transgene was
injected into the VTA of Vgat-ires-cre mice to express
inhibitory halorhodopsin in VTAVgat neurons to generate
VTAVgat-NpHR mice (Fig. 5e). Optic fibers were placed
above the LH of VTAVgat-NpHR mice, where dense NpHR-
mCherry projections arising from the VTAVgat cell bodies
can be seen (Fig. 5e). Optogenetic inhibition of the VTAVgat
to LH projection, by activating NpHR-mCherry in the LH,
elevated the locomotion of mice in the open field (Fig. 5f),
whereas it decreased the immobility times during the TST
(Fig. 5g) and FST (Fig. 5h). We confirmed this using spe-
cific chemogenetic inhibition of the VTAVgat to LH pro-
jection. CNO was infused directly into the LH of VTAVgat-
hM4Di mice, which expressed the inhibitory CNO receptor
in VTAVgat neurons (Supplementary Fig. 9a). CNO infusion
increased locomotion speed (Supplementary Fig. 9b), and
decreased immobility time during the TST (Supplementary
Fig. 9c). These results indicate that inhibiting GABAergic
tone from VTAVgat neurons to the LH produces hyperlo-
comotion and less depressive-like behaviors. We next
injected AAV-DIO-ChR2-mCherry into the VTA of Vgat-
cre mice to express excitatory channel rhodopsins in VTA
GABAergic cells. Although opto-activation of the VTAVgat
to LH projection did not affect the locomotion of mice in
the open field (Fig. 5i), it did increase the immobility times
during the TST (Fig. 5j) and FST (Fig. 5k). The above
results suggest that the VTAVgat to LH projection, together
with VTAVgat local inhibition of the dopamine system,
contributes to generating mania-like behaviors.
Discussion
We found that endophenotypes (hyperactivity, elevated
mood, and reduced sleep) resembling aspects of mania
could be produced by lesion or acute inhibition of
GABAergic VTAVgat neurons. In mice with lesioned or
inhibited VTAVgat neurons, D-amphetamine further
increased the hyperactivity, suggesting the mania-like
behavior of these mice could be the type associated with
bipolar disorder in humans. The mania effects were partially
blocked by D1, D2, and D3 receptor antagonists. Thus,
hyperdopaminergia could originate from VTAVgat cells
failing to inhibit dopamine neurons (Fig. 5l). VTAVgat cells,
however, are not simply VTA inhibitory interneurons that






































35 40 45 50 55 60















































Chemogenetic activation of VTAVglut2 neuronsa
Slice electrophysiology of VTAVglut2 neurons
VTAVglut2-hM3Dq mouse injected with saline or CNO
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 Tail suspension test (TST)  Forced swimming test (FST)
Fig. 4 Activation of VTAVglut2 neurons does not produce mania-
like behaviors. a Generation of VTAVglut2-hM3Dq mice. Staining by
immunohistochemistry (mCherry) for hM3Dq-mCherry expression in
the VTA. Scale bar: 150 μm. b Example of a spontaneously active
VTA glutamatergic neuron with action potential firing before,
during and after CNO application in an acute brain slice prepared
from a VTAVglut2-hM3Dq mouse. The bar graph shows the
average normalized frequency of action potentials of all cells recorded.
One-way repeated ANOVA and Bonferroni-Holm post hoc test.
F(baseline CNO washout)= 35, baseline vs. CNO t(22)= 7.64, ****p= 1E-
7, CNO vs. washout t(22)= 6.91, ****p= 6E-7, baseline vs. washout
t(22)= 0.72, p= 0.4. c Video-tracked paths, locomotion speed and
distance traveled of VTAVglut2-hM3Dq mice (n= 8 mice) following
CNO (1 mg/kg) injection compared with saline injection in the open
field arena over a 30-min period. Paired t-test, t(7)=−0.72, p= 0.49.
d Immobility time during the tail suspension test (TST) of VTAVglut2-
hM3Dq mice (n= 8 mice) after saline or CNO injection. Paired t-test,
t(7)=−0.73, p= 0.88. e Immobility time during the forced swimming
test (FST) of VTAVglut2-hM3Dq mice (n= 6 mice) after saline or CNO
injection. Paired t-test, t(4)=−0.01, p= 0.98.
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promoting increased movement in the FST and TST
depends on their inhibitory projections to the LH. Our
results on hyperactivity produced by disinhibiting LH
circuits are consistent with previous findings. In rats,
repeated delivery of subthreshold stimuli (kindling) to the
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promotes physical activity and motivated behavior [50]; LH
lesions in rodents and people produce a state of wakefulness
with no motion [51]. The LH contains orexin/glutamate
neurons that promote arousal, motivation and energy
expenditure [52], and GABAergic neurons whose activation
induces wakefulness and locomotion [50, 53, 54]. It is
likely that the VTAVgat neurons inhibit both the orexin
neurons and/or the arousal/locomotor- promoting GABA
neurons in the LH [28, 36].
Given the hub-like nature of the GABAergic VTAVgat
neurons, the mania phenotype produced by lesioning or
inhibiting these neurons is likely a consequence of
the disinhibition of multiple targets, e.g., dopamine cells in
the VTA, but also to some extent other cell types in the LH.
On the other hand, VTAVgat neurons also locally
inhibit VTA glutamate neurons [28], but disinhibition of
glutamate neurons in the VTA by lesioning or inhibiting
the VTAVgat neurons probably does not contribute to the
mania-phenotype. Direct pharmacogenetic excitation
of these glutamate cells produces calm wakefulness (Fig. 4)
[28].
Inability to sleep is one of the diagnostic criteria for the
mania phase of bipolar disorder [2, 3, 55], and certainly
VTAVgat mice sleep consistently less than control mice,
such that they have 100% wakefulness during the “lights
off” phase compared with control mice that take about 4 h
NREM sleep during this time [28]. Usually, the longer that
wakefulness persists, the stronger the urge to sleep
becomes, until sleep is inescapable. A remarkable finding is
that VTAVgat-CASP3 mice bypassed the homeostatic pro-
cess of having NREM recovery sleep after sleep deprivation
—they did not catch up on lost sleep in spite of already
starting from a strongly sleep-deprived background. The
mechanisms underlying sleep homeostasis are not well
understood [48, 56, 57]. Sleep homeostasis is thought to
reflect the function of sleep, (otherwise why catch up on lost
sleep?), and it will be interesting to investigate if the chronic
lack of sleep of VTAVgat-CASP mice will be detrimental
metabolically.
Sleep deprivation can sometimes trigger mania episodes
in humans [3, 55, 58]. Consequently, an interesting question
is whether the chronic sleep deprivation phenotype of
VTAVgat-CASP3 mice actually causes their mania-like
symptoms. Mice chronically sleep derived with the flower
pot method—the animals stay on top of a raised platform
surrounded by water, and when they fall asleep, they fall
into water and wake up—also develop mania-like behavior
[59]. This type of sleep deprivation is, however, likely to be
stressful. In the VTAVgat-CASP3 mice, the sleep-
deprivation phenotype is internally generated within the
brain, and could be less stressful per se.
The mania-like behaviors of VTAVgat-CASP3 mice,
including the strong sleep loss and abnormal sleep
Fig. 5 Circuit mechanisms underlying the mania-like behaviors
mediated by VTAVgat neurons. a Locomotion speed and distance
traveled of VTAVgat-hM4Di mice that received injections with
vehicle or a dopamine receptor antagonist mixture (SCH-23390 and
raclopride for D1 and D2/D3 receptors, respectively) and
either saline (n= 7 mice) or CNO (n= 7 mice). Two-way
ANOVA and Bonferroni-Holm post hoc test. F(saline or CNO)= 13.6;
F(vehicle or antagonists)= 91.2; F(interaction)= 7.4; Vehicle+ saline vs.
antagonists+ saline t(12)= 5, ***p= 0.0002; Vehicle + CNO vs.
antagonists+ CNO t(12)= 8.34, ****p= 2E−6. All error bars
represent the SEM. b Locomotion speed and distance traveled of
VTAVgat-mCherry and VTAVgat-CASP3 mice that received injections
with either vehicle (n= 6 mice for mCherry and n= 10 mice for
CASP3) or a dopamine receptor antagonist mixture (n= 6 mice for
mCherry and n= 13 mice for CASP3). Two-way ANOVA
and Bonferroni-Holm post hoc test. F(mCherry or CASP3)= 10.8;
F(saline or antagonists)= 4.5; F(interaction)= 0.03; mCherry + vehicle vs.
mCherry + antagonists t(10)= 4.14, **p= 0.002; CASP3+ vehicle
vs. CASP3+ antagonists t(21)= 1.64, p= 0.11. All error bars
represent the SEM. c Time spent immobile for the tail suspension
assay of VTAVgat-hM4Di mice that received injections of
either vehicle or the dopamine receptor antagonist mixture and saline
or CNO. Two-way ANOVA and Bonferroni–Holm post hoc test.
F(saline or CNO)= 36; F(Vehicle or antagonists)= 27; F(interaction)= 0.35;
vehicle + saline vs. antagonists + saline t(12)=−7.59, ****p=
6E−6; vehicle + CNO vs. antagonists + CNO t(12)=−2.54,
*p= 0.02; antagonists + saline vs. antagonists + CNO t(12)= 3.8,
**p= 0.002. All error bars represent the SEM. d Time spent
immobile for the tail suspension assay of VTAVgat-mCherry and
VTAVgat-CASP3 mice that received injections of either vehicle (n=
8 mice for mCherry and n= 9 mice for CASP3) or the dopamine
receptor antagonist mixture (n= 8 mice for mCherry and n= 9 mice
for CASP3). Two-way ANOVA and Bonferroni-Holm post hoc test.
F(mCherry or CASP3)= 209; F(saline or antagonists)= 25; F(interaction)= 4.38;
mCherry+ vehicle vs. mCherry + antagonists t(14)=−4.87,
***p= 0.0002; CASP3+ vehicle vs. CASP3+ antagonists t(16)=
−2.16, *p= 0.04; mCherry+ antagonists vs. CASP3+ antagonists t
(15)= 13, ****p= 7e−10. All error bars represent the SEM. e AAV-
DIO-NpHR-mCherry was injected the VTA of Vgat-ires-cre mice,
and optic fibers were bilaterally implanted above the LH. The NpHR-
mCherry fibers projecting from the VTAVgat neurons into the LH
were stained by immunohistochemistry (mCherry, red). Scale bar:
200 μm. f Video-tracked paths and distance traveled in the open field
by VTAVgat-NpHR mice (n= 7 mice) with and without opto-
inhibition of VTAVgat terminals in the LH over 5 minute period.
Paired t-test, t(6)=−4.08, **p= 0.006. g Time spent immobile on
the tail suspension test (TST) of VTAVgat-NpHR mice (n= 7 mice)
with and without opto-inhibition of VTAVgat terminals in the LH.
Paired t-test, t(6)= 5.3, **p= 0.001. h Time spent immobile on the
forced swimming test (FST) of VTAVgat-NpHR mice (n= 6 mice)
with and without opto-inhibition of VTAVgat terminals in the LH.
Paired t-test, t(5)= 6.77, **p= 0.001. i Video-tracked paths and
distance traveled in the open field by VTAVgat-ChR2 mice (n= 8
mice) with and without opto-activation of VTAVgat terminals in the
LH over 5-minute period. Paired t-test, t(7)= 0.18, p= 0.85. j Time
spent immobile on the tail suspension test (TST) of VTAVgat-ChR2
mice (n= 8 mice) with and without opto-activation of VTAVgat
terminals in the LH. Paired t-test, t(7)=−3.11, *p= 0.01. k Time
spent immobile on the forced swimming test (FST) of VTAVgat-
ChR2 mice (n= 6 mice) with and without opto-activation of VTAVgat
terminals in the LH. Paired t-test, t(5)=−4, *p= 0.01. l Conceptual
circuit diagram illustrating VTAVgat neurons inhibiting VTA dopa-
mine (DA) neurons and circuitry in the LH. When the VTAVgat cells
have acutely diminished or absent function, activity of VTA dopa-
mine neurons and arousal-promoting neurons in the LH increase.
Valproate can reverse the effects of these changes.
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architecture, were reversed by valproate, and re-emerged
when valproate treatment was stopped. Valproate has
diverse actions: for example, it enhances GABAergic
transmission and reduces action potential firing (reviewed in
ref. 13), but by inhibiting histone deacetylases [60, 61],
valproate treatments also change the expression of many
genes. We found that low doses of diazepam were also
efficacious in reducing the hyperarousal of VTAVgat-CASP3
mice. Diazepam a GABAA receptor positive allosteric
modulator, enhances GABA transmission [62]. At the low
doses tested here in mice, diazepam is an anxiolytic, but at
higher doses (which we did not test) it induces sleep [62].
Two other important drugs used for treating bipolar dis-
order, lithium and lamotrigine, had no effect in treating
VTAVgat-CASP3 mice. Although its mechanism of action is
unclear, lithium treatment is the first choice to treat mania
episodes, although a subset of bipolar patients with rapidly
cycling mania and depression phases are resistant to lithium
(reviewed in ref 13). In most mouse models of mania, both
valproate and lithium are usually effective treatments
(reviewed in ref. 1). But similar to our results, mice with
SHANK3 overexpression in the neocortex, hippocampus
and basal ganglia, have mania-like symptoms treatable with
valproate but not lithium [13]. Similar arguments could
apply to lamotrigine. It could be that the VTAVgat-CASP3
mice and SHANK3-overexpressing mice models reflect a
specific mania type.
In summary, the model based on reducing VTAVgat
neuronal function could provide further insight into the
genesis of some types of mania-like behaviors. One
hypothesis is that VTAVgat neurons help set the level of
mental and physical activity. Physiologically, inputs that
inhibit VTAVgat neurons will transiently intensify aspects
of wakefulness useful for acute success or survival:
increased activity, enhanced alertness and motivation,
reduced sleep (Fig. 5l). Taken to the extreme, however,
pathology could emerge and decreased or failed inhibition
from VTAVgat neurons will produce mania-like qualities
(Fig. 5l).
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